FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, specifically to oncology, and relates to a method for determining the degree of risk of an adverse outcome of a disease in patients with gastric cancer. Essence of the method: in the stomach tumor, the total calpain activity is determined, Chymotrypsin-like total proteasome activity, activity of 26S and 20S proteasome pools, content of subunits amount α Σα, content of the LMP7 subunit, content of the LMP2 subunit, content of the PA28β, subunit, content of the Rpt6 subunit, also take into account the age of the patients. Then, the values of the discriminant functions Y1, Y2 are calculated from the equations. At Y1>Y2, a low, and at Y1<Y2 – high risk of adverse outcome of stomach cancer, in the case when the characteristics of the object presented for recognition satisfy the condition Y1=Y2, recognition is impossible without additional information. Sensitivity of the method is 67 %, the specificity is 96 %.
EFFECT: increasing the accuracy of the method.
1 cl, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DISTANT METASTASES DEVELOPMENT RISK DEGREE DETERMINATION FOR PATIENTS WITH COLON CANCER | 2016 |
|
RU2623119C1 |
METHOD FOR PREDICTION OF DISEASE OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER SURGICAL MANAGEMENT | 2018 |
|
RU2696054C1 |
METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
METHOD FOR ASSESSING ENDOMETRIAL CANCER PROGRESSION IN PATIENTS WITH HYPERPLASTIC PROCESSES IN ENDOMETRIUM | 2014 |
|
RU2554505C1 |
METHOD OF DETERMINING THE RISK OF MALIGNANT TRANSFORMATION OF EPITHELIAL CELLS OF THE LARYNX IN PATIENTS WITH PRECANCEROUS DISEASES OF THE LARYNX | 2022 |
|
RU2803858C1 |
METHOD FOR PREDICTION OF DEVELOPING LYMPHOGENIC METASTASES IN SQUAMOUS CELL CARCINOMA OF HEAD AND NECK FOLLOWING COMBINATION THERAPY | 2013 |
|
RU2527338C1 |
METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
METHOD OF PERSONIFIED PRESCRIBING OF TARGETED THERAPY AGENTS IN PATIENTS WITH METASTATIC KIDNEY CANCER IN PREOPERATIVE MODE | 2017 |
|
RU2650964C1 |
METHOD FOR PREDICTION OF CLINICAL OUTCOME OF MUSCULO-INVASIVE BLADDER CANCER FOLLOWING COMBINATION THERAPY | 2012 |
|
RU2538632C2 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
Authors
Dates
2018-07-23—Published
2016-06-22—Filed